4D Molecular Therapeutics
4D Molecular Therapeutics
FDMT
NASDAQ
15.01
USD
221.41%
About
4D Molecular Therapeutics, Inc. is a clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat diseases in ophthalmology and pulmonology. The Company has a portfolio of genetic medicine product candidates, with five product candidates in clinical trials in seven patient populations: 4D-150 for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME), 4D-710 for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations), 4D-310 for the treatment of Fabry disease cardiomyopathy, 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP), and 4D-110 for the treatment of choroideremia.
In addition, it has two product candidates in preclinical development: 4D-175 for geographic atrophy (GA) and 4D-725 for alpha-1 antitrypsin deficiency lung disease..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 443.8K |
| Three Month Average Volume | 18.7M |
| High Low | |
| Fifty-Two Week High | 36.25 USD |
| Fifty-Two Week Low | 9.44 USD |
| Fifty-Two Week High Date | 27 Mar 2024 |
| Fifty-Two Week Low Date | 17 Oct 2023 |
| Price and Volume | |
| Current Price | 15.01 USD |
| Beta | 3 |
| Relative Price Change | |
| Four Week Relative Price Change | -11.70% |
| Thirteen Week Relative Price Change | -41.49% |
| Twenty-Six Week Relative Price Change | -53.52% |
| Fifty-Two Week Relative Price Change | -26.42% |
| Year-to-Date Relative Price Change | -37.44% |
| Price Change | |
| One Day Price Change | -1.57% |
| Thirteen Week Price Change | -37.38% |
| Twenty-Six Week Price Change | -48.89% |
| Five Day Price Change | 0.33% |
| Fifty-Two Week Price Change | -7.80% |
| Year-to-Date Price Change | -25.91% |
| Month-to-Date Price Change | -15.34% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 7.14631 USD |
| Book Value Per Share (Most Recent Quarter) | 11.33291 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 7.14631 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 11.33291 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.72228 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0.52959 USD |
| Revenue Per Share (Trailing Twelve Months) | 0.43495 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.57697 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.21778 USD |
| Normalized (Last Fiscal Year) | -2.57697 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.57697 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.21778 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.57697 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.21778 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 6.69136 USD |
| Cash Per Share (Most Recent Quarter) | 10.43925 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.46452 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.26355 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -1.87511 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -555 |
| Cash Flow Revenue (Trailing Twelve Months) | -431 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -543.51% |
| Pretax Margin (Last Fiscal Year) | -486.59% |
| Pretax Margin (5 Year) | -617.15% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -544.65% |
| Operating Margin (Trailing Twelve Months) | -648.98% |
| Operating Margin (5 Year) | -642.78% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -486.59% |
| Net Profit Margin (Trailing Twelve Months) | -543.51% |
| Net Profit Margin (5 Year) | -617.15% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -13.00% |
| Tangible Book Value (5 Year) | 32.49% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -97.91% |
| Revenue Growth (3 Year) | 7.96% |
| Revenue Change (Trailing Twelve Months) | 785.25% |
| Revenue Per Share Growth | -27.74% |
| Revenue Growth (5 Year) | 15.04% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | 46.26% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 18.16% |
| EPS Change (Trailing Twelve Months) | 32.49% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 3 |
| Price to Tangible Book (Most Recent Quarter) | 1 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -541,946,000 |
| Net Debt (Last Fiscal Year) | -288,232,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | 38 |
| Price to Sales (Trailing Twelve Months) | 39 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | 9 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | 9 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 2 |
| Price to Book (Most Recent Quarter) | 1 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 16 |
| Current Ratio (Most Recent Quarter) | 28 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -78,563,000 |
| Free Cash Flow (Trailing Twelve Months) | -87,165,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -33.52% |
| Return on Assets (Trailing Twelve Months) | -22.60% |
| Return on Assets (5 Year) | -32.67% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -37.40% |
| Return on Equity (Trailing Twelve Months) | -24.06% |
| Return on Equity (5 Year) | -44.13% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -35.57% |
| Return on Investment (Trailing Twelve Months) | -23.39% |
| Return on Investment (5 Year) | -34.90% |